Display options
Cite
Murillo-Ortiz B, Martínez-Garza S, Suárez García D, et al. Association between telomere length and CYP19 TTTA repetition polymorphism in healthy and breast cancer-diagnosed women. Breast Cancer (Dove Med Press). 2017;9:21-27doi: 10.2147/BCTT.S125431.
Murillo-Ortiz, B., Martínez-Garza, S., Suárez García, D., Castillo Valenzuela, R. D., García Regalado, J. F., & Cano Velázquez, G. (2017). Association between telomere length and CYP19 TTTA repetition polymorphism in healthy and breast cancer-diagnosed women. Breast cancer (Dove Medical Press), 921-27. https://doi.org/10.2147/BCTT.S125431
Murillo-Ortiz, Blanca, et al. "Association between telomere length and CYP19 TTTA repetition polymorphism in healthy and breast cancer-diagnosed women." Breast cancer (Dove Medical Press) vol. 9 (2017): 21-27. doi: https://doi.org/10.2147/BCTT.S125431
Murillo-Ortiz B, Martínez-Garza S, Suárez García D, Castillo Valenzuela RD, García Regalado JF, Cano Velázquez G. Association between telomere length and CYP19 TTTA repetition polymorphism in healthy and breast cancer-diagnosed women. Breast Cancer (Dove Med Press). 2017 Jan 13;9:21-27. doi: 10.2147/BCTT.S125431. eCollection 2017. PMID: 28144163; PMCID: PMC5245810.
Copy Download .nbib Format: NLM
Share it on

Breast Cancer (Dove Med Press). 2017 Jan 13;9:21-27. doi: 10.2147/BCTT.S125431. eCollection 2017.

Association between telomere length and CYP19 TTTA repetition polymorphism in healthy and breast cancer-diagnosed women.

Breast cancer (Dove Medical Press)

Blanca Murillo-Ortiz, Sandra Martínez-Garza, David Suárez García, Rosa Del Carmen Castillo Valenzuela, Juan Francisco García Regalado, Gerardo Cano Velázquez

Affiliations

  1. Institute Mexican of Social Security, Department Oncology, Unit of Research in Clinical Epidemiology.
  2. Department of Medical Sciences, University of Guanajuato, León Guanajuato, Mexico.

PMID: 28144163 PMCID: PMC5245810 DOI: 10.2147/BCTT.S125431

Abstract

INTRODUCTION: Several studies have reported an increase in breast cancer (BC) risk when patients are carriers of the CYP19 TTA polymorphism with ≥10 repeats; moreover, it has been reported that telomere length is associated with a higher susceptibility of developing cancer.

OBJECTIVE: The objective of this study was to understand the relationship between CYP19 TTTA repetition polymorphism and telomere length and its effects on serum estradiol, estrone and follicle-stimulating hormone (FSH).

MATERIALS AND METHODS: A total of 180 postmenopausal healthy and 70 BC-diagnosed women were included. Telomere length was determined through real-time quantitative polymerase chain reaction, and aromatase polymorphism was analyzed through DNA; both samples were obtained from circulating leukocytes. Serum estrone, estradiol and FSH were determined by enzyme-linked immunosorbent assay.

RESULTS: Patients with a BC diagnosis showed >10 repetitions more frequently, compared with that of healthy women (50% vs 23%,

CONCLUSION: Telomere length is shorter in BC patients than in healthy patients. The CYP19 TTTA repeat polymorphism is associated with serum levels of estradiol and estrone in both healthy women and BC patients, being higher in those with polymorphism carriers >10 repeats. Telomere length has an inverse correlation with the number of repeats of the aromatase polymorphism in healthy women but not in BC women. Estradiol and estrone levels in BC women have an inverse relationship with telomere length.

Keywords: CYP19 polymorphism; breast cancer; telomere length

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

  1. Toxicol Lett. 2006 Jun 20;164(1):90-5 - PubMed
  2. J Natl Cancer Inst. 2003 Aug 20;95(16):1211-8 - PubMed
  3. Cancer Res. 2007 Mar 1;67(5):1893-7 - PubMed
  4. Curr Biol. 2008 Apr 8;18(7):496-500 - PubMed
  5. Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):815-9 - PubMed
  6. PLoS Med. 2014 Jul 08;11(7):e1001673 - PubMed
  7. J Carcinog. 2006 May 09;5:12 - PubMed
  8. Cancer Res. 1999 Dec 1;59(23):5917-21 - PubMed
  9. Aging Cell. 2009 Feb;8(1):45-51 - PubMed
  10. Cancer Res. 2007 Jun 1;67(11):5538-44 - PubMed
  11. Int J Cancer. 2009 Apr 1;124(7):1637-43 - PubMed
  12. Zhonghua Liu Xing Bing Xue Za Zhi. 2006 Apr;27(4):351-5 - PubMed
  13. Sci Rep. 2016 Feb 26;6:22243 - PubMed
  14. Oncogene. 2000 Mar 2;19(10):1329-33 - PubMed
  15. Cell Res. 2008 Nov;18(11):1141-50 - PubMed
  16. Int J Cancer. 2000 Jul 20;89(4):325-8 - PubMed
  17. Breast Cancer Res Treat. 2004 May;85(2):121-31 - PubMed
  18. Oncologist. 2008 Jul;13(7):751-60 - PubMed
  19. PLoS One. 2013;8(1):e53902 - PubMed
  20. J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):219-24 - PubMed
  21. Cancer Res. 2010 Apr 15;70(8):3170-6 - PubMed
  22. Cancer Res. 2008 May 15;68(10):3618-23 - PubMed
  23. Breast Cancer Res Treat. 2009 Mar;114(2):327-38 - PubMed
  24. Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1152-6 - PubMed
  25. Nucleic Acids Res. 2002 May 15;30(10):e47 - PubMed

Publication Types